O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+30.47%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.45B
AUM Growth
+$5.45B
(+9.1%)
Cap. Flow
-$287M
Cap. Flow
% of AUM
-5.27%
Top 10 Holdings %
Top 10 Hldgs %
39.03%
Holding
130
New
20
Increased
22
Reduced
29
Closed
17
Top Buys
| 1 |
ArriVent BioPharma
AVBP
|
$54.1M |
| 2 |
Cytokinetics
CYTK
|
$47.9M |
| 3 |
Geron
GERN
|
$40.9M |
| 4 |
Q32 Bio
QTTB
|
$38.4M |
| 5 |
Esperion Therapeutics
ESPR
|
$36.7M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.34% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Praxis Precision Medicines
PRAX
$958M
| $28.1M | 0.51% | +460,512 | New | +$28.1M |
|
52
Heron Therapeutics
HRTX
$207M
| $28M | 0.51% | 10,111,550 +4,182,959 | +71% | +$11.6M |
|
53
scPharmaceuticals
SCPH
$295M
| $27.9M | 0.51% | 5,559,528 | – | – |
|
|
SLRN
54
DELISTED
ACELYRIN
SLRN
| $27M | 0.49% | 4,001,711 | – | – |
|
55
Adicet Bio
ACET
$59.9M
| $26.9M | 0.49% | 11,447,140 +3,125,000 | +38% | +$7.34M |
|
56
Mineralys Therapeutics
MLYS
$1.03B
| $26.1M | 0.48% | +2,021,424 | New | +$26.1M |
|
57
Avidity Biosciences
RNA
$5.99B
| $25.4M | 0.46% | +994,100 | New | +$25.4M |
|
58
Xenon Pharmaceuticals
XENE
$2.98B
| $23.7M | 0.43% | 550,000 | – | – |
|
59
Regeneron Pharmaceuticals
REGN
$61.5B
| $21.9M | 0.4% | 22,800 +9,300 | +69% | +$8.95M |
|
|
KNTE
60
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $21.3M | 0.39% | 8,009,729 | – | – |
|
61
Arrowhead Research
ARWR
$3.05B
| $21.2M | 0.39% | 739,651 +420,000 | +131% | +$12M |
|
62
Neumora Therapeutics
NMRA
$280M
| $20.6M | 0.38% | 1,500,000 | – | – |
|
63
Dyne Therapeutics
DYN
$1.92B
| $20.1M | 0.37% | +708,400 | New | +$20.1M |
|
|
MORF
64
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $19.7M | 0.36% | 558,500 +285,100 | +104% | +$10M |
|
65
DexCom
DXCM
$29.5B
| $19.5M | 0.36% | 140,300 +67,100 | +92% | +$9.31M |
|
66
AbCellera Biologics
ABCL
$1.25B
| $18.9M | 0.35% | 4,180,768 | – | – |
|
67
Immatics
IMTX
$619M
| $18.6M | 0.34% | 1,769,708 +226,301 | +15% | +$2.38M |
|
68
Verastem
VSTM
$569M
| $18M | 0.33% | 1,529,115 | – | – |
|
69
Amgen
AMGN
$155B
| $18M | 0.33% | 63,400 -63,900 | -50% | -$18.2M |
|
|
JBIO
70
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $16.7M | 0.31% | 565,374 -191,556 | -25% | -$5.66M |
|
71
TELA Bio
TELA
$70.5M
| $16.1M | 0.29% | 2,835,542 | – | – |
|
72
Repare Therapeutics
RPTX
$71.7M
| $15.6M | 0.29% | 3,322,488 | – | – |
|
73
Passage Bio
PASG
$22.7M
| $13.7M | 0.25% | 10,124,576 | – | – |
|
74
Tyra Biosciences
TYRA
$675M
| $12.6M | 0.23% | +768,638 | New | +$12.6M |
|
75
Corvus Pharmaceuticals
CRVS
$428M
| $12.4M | 0.23% | 6,943,654 | – | – |
|